Immix Biopharma Files 2024 Annual Report Amendment
Ticker: IMMX · Form: 10-K/A · Filed: May 19, 2025 · CIK: 1873835
Sentiment: neutral
Topics: amendment, annual-report, pharmaceuticals
TL;DR
Immix Biopharma filed its amended 2024 10-K, check for updates.
AI Summary
Immix Biopharma, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, submitted on May 19, 2025, provides updated information for the company, which is incorporated in Delaware and headquartered in Los Angeles, California.
Why It Matters
This amendment to the annual report provides updated financial and operational information for Immix Biopharma, Inc., which is crucial for investors and stakeholders to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This filing is an amendment to a standard annual report and does not appear to contain significant new negative information.
Key Numbers
- 2024 — Fiscal Year End (The report covers the fiscal year ending December 31, 2024.)
- 20250519 — Filing Date (This amendment was filed on May 19, 2025.)
Key Players & Entities
- Immix Biopharma, Inc. (company) — Registrant
- 0001873835 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
- DE (company) — State of Incorporation
- 454869378 (company) — IRS Employer Identification No.
- 11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064 (company) — Principal Executive Offices Address
- 001-41159 (company) — Commission File Number
- December 31, 2024 (date) — Fiscal Year End
- May 19, 2025 (date) — Filing Date
FAQ
What is the purpose of this 10-K/A filing?
This filing is an amendment (Amendment No. 1) to the Annual Report (Form 10-K) for the fiscal year ended December 31, 2024, for Immix Biopharma, Inc.
When was this amendment filed with the SEC?
This amendment was filed on May 19, 2025.
What is Immix Biopharma, Inc.'s fiscal year end?
Immix Biopharma, Inc.'s fiscal year ends on December 31.
Where is Immix Biopharma, Inc. headquartered?
Immix Biopharma, Inc.'s principal executive offices are located at 11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064.
What is the company's Standard Industrial Classification code?
The company's Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on May 19, 2025 regarding Immix Biopharma, Inc. (IMMX).